Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naive Psoriatic Arthritis Patients

被引：0

作者：

Vieira-Sousa, Elsa ^{[1
]}

Alves, Pedro ^{[2
]}

Rodrigues, Ana Maria ^{[3
]}

Teixeira, Filipa ^{[4
]}

Tavares-Costa, Jose ^{[5
]}

Bernardo, Alexandra ^{[6
]}

Pimenta, Sofia ^{[6
]}

Pimentel-Santos, Fernando ^{[7
]}

Gomes, Joao Lagoas ^{[8
,9
]}

Aguiar, Renata ^{[10
]}

Pinto, Patricia ^{[11
]}

Videira, Taciana ^{[11
]}

Catita, Cristina ^{[12
]}

Santos, Helena ^{[13
]}

Borges, Joana ^{[14
]}

Sequeira, Graca ^{[15
]}

Ribeiro, Celia ^{[15
]}

Teixeira, Lidia ^{[16
]}

Avila-Ribeiro, Pedro ^{[17
,18
,19
]}

Martins, Fernando M. ^{[20
]}

Canhao, Helena ^{[21
]}

Ribeiro, Ruy M. ^{[22
]}

Fonseca, Joao Eurico ^{[17
,18
,19
]}

机构：

[1] Univ Lisbon, Lisbon Acad Med Ctr, Fac Med,Rheumatol & Metab Bone Dis,Hosp Santa Mar, Ctr Hosp Lisboa Norte EPE,Rheumatol Res Unit,Inst, Lisbon, Portugal

[2] CHLC, Radiol Dept, Lisbon, Portugal

[3] Ctr Acad Med Lisboa, HSEIT Ilha Terceira Acores & FMUL, Rheumatol Unit, Lisbon, Portugal

[4] ULSAM, Rheumatol Dept, Ponte do Lima, Portugal

[5] ULSAM, Ponte do Lima, Portugal

[6] CHSJ, Rheumatol Dept, Porto, Portugal

[7] CHLO, Hosp Egas Moniz, NOVA Med Sch, CEDOC, Lisbon, Portugal

[8] Ctr Hosp Lisboa Ocident, Hosp Egas Moniz, Rheumatol Dept, Lisbon, Portugal

[9] NOVA Med Sch, Fac Ciencias Med, CEDOC, Lisbon, Portugal

[10] CHBV, Rheumatol Dept, Aveiro, Portugal

[11] CHVNG, Rheumatol Dept, Vila Nova De Gaia, Portugal

[12] Hosp Particular Algarve, Faro, Portugal

[13] IPR, Lisbon, Portugal

[14] Inst Portugues Reumatol, Lisbon, Portugal

[15] CHA, Rheumatol Unit, Faro, Portugal

[16] HGO, Rheumatol Dept, Almada, Portugal

[17] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Rheumatol & Bone Dis Dept, Lisbon, Portugal

[18] Univ Lisbon, Fac Med, Inst Med Mol, Unidade Invest Reumatol, Lisbon, Portugal

[19] Ctr Acad Med Lisboa, Lisbon, Portugal

[20] Portuguese Soc Rheumatol, Lisbon, Portugal

[21] NOVA Med Sch, EpiDoC Unit, CEDOC, Lisbon, Portugal

[22] FMUL, Lab Biomatemat, Lisbon, Portugal

来源：

ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2876

引用

页数：2

共 41 条

[31] Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
McInnes, Iain B.
Sieper, Joachim
Braun, Juergen
Emery, Paul
van der Heijde, Desiree
Isaacs, John D.
Dahmen, Georg
Wollenhaupt, Juergen
Schulze-Koops, Hendrik
Kogan, Joseph
Ma, Shenglin
Schumacher, Martin M.
Bertolino, Arthur P.
Hueber, Wolfgang
Tak, Paul P.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (02) : 349 - 356
[32] Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study.
Fleischmann, Roy
Decktor, Dennis L.
Fan, Chunpeng
Van Hoogstraten, Hubert
Genovese, Mark C.
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1232 - S1233
[33] Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
Ogdie-Beatty, Alexis
Merola, Joseph
Mease, Philip
Ritchlin, Christopher
Scher, Jose
Chan, Daphne
Chakravarty, Soumya
Langholff, Wayne
Choi, Olivia
Krol, Yevgeniy
Rowland, Katelyn
Gottlieb, Alice
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3766 - 3768
[34] Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
McInnes, Iain
Anderson, Jaclyn K.
Magrey, Marina
Merola, Joseph
Liu, Yi
Kishimoto, Mitsumasa
Jeka, Slawomir
Tena, Cesar Pacheco
Wang, Xin
Chen, Liang
Zueger, Patrick
Pangan, Aileen
Behrens, Frank
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[35] RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
Hsu, B.
Sheng, S.
Smolen, J. S.
Weinblatt, M. E.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 188 - 188
[36] Results From a 2-Part, Proof-of-Concept, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-Interleukin-6 Monoclonal Antibody, in Active Rheumatoid Arthritis Patients Despite Methotrexate Therapy.
Hsu, Benjamin
Sheng, Shihong
Smolen, Josef
Weinblatt, Michael
ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1034 - S1034
[37] Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
Ogdie, Alexis
Merola, Joseph F.
Mease, Philip J.
Ritchlin, Christopher T.
Scher, Jose U.
Lafferty, Kimberly Parnell
Chan, Daphne
Chakravarty, Soumya D.
Langholff, Wayne
Wang, Yanli
Choi, Olivia
Krol, Yevgeniy
Gottlieb, Alice B.
BMC RHEUMATOLOGY, 2024, 8 (01)
[38] EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
Mcinnes, I.
Anderson, J.
Magrey, M.
Merola, J. F.
Liu, Y.
Kishimoto, M.
Jeka, S.
Tena, C. F. Pacheco
Wang, X.
Chen, L.
Zueger, P.
Pangan, A.
Behrens, F.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 12 - 13
[39] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing
Kavanaugh, Arthur
McInnes, Iain B.
Mease, Philip J.
Hall, Stephan
Chinoy, Hector
Kivitz, Alan J.
Patekar, Manmath
Wang, Zailong
Mpofu, Shephard
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[40] Secukinumab provides sustained improvements in the signs and symptoms of Active Psoriatic Arthritis in Anti. TNF-Naive patients and those previously exposed to Anti-TNF Therapy: 52-week results from a randomized, double-blind, placebo-controlled phase 3 trial with subcutaneous dosing
Hall, S.
Kavanaugh, A.
McInnes, I.
Mease, P.
Chinoy, H.
Kivitz, A.
Patekar, M.
Wang, Z.
Mpofu, S.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 53 - 53

← 1 2 3 4 5 →